Medical News

RSS

5,000 rare diseases need drugs, but Europe only approves a handful each year

Only seven per cent of drug applications for treating people with rare diseases were approved in Europe between 2000 and 2004, despite the fact that there are currently more than 5,000 conditions needing medication.

6 Mar 2006

Photodynamic therapy lighting the way for medical treatments

For the millions of people who suffer from acne, sun damage or even worse, skin cancer, there is a light of hope - photodynamic therapy or PDT.

6 Mar 2006

Data from Novogen inflammatory bowel disease drug Phase I clinical trial shows promise

A recently completed Phase 1 clinical trial of an investigational drug to treat inflammatory bowel disease has demonstrated rapid absorption indicating potential for development as an oral therapy.

6 Mar 2006

Next-generation drug development: risky and costly, but worth it

Generic drugs, which drive a $40 billion dollar generics industry expected to hit $60 billion by 2007, account for 53% of all prescriptions filled in the United States today.

6 Mar 2006

Topical therapies show promise for Psoriasis

Psoriasis, a chronic skin condition characterized by thick, red, scaly patches that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.

6 Mar 2006

Individualized treatment options for rosacea

Many individuals who are struggling with redness, pimples and visible blood vessels on their face may incorrectly diagnose their condition as acne, sunburn or sensitive skin.

6 Mar 2006

UCB submits application to FDA for new treatment in Crohn's disease

UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.

6 Mar 2006

Reports of bird flu in the Bahamas are exaggerated

Preliminary field reports on the investigation of unexplained death of birds on the island of Inagua in the Southern Bahamas were exaggerated.

6 Mar 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Study shows new atopic dermatitis therapy significantly delays onset of flares

Stiefel Laboratories, the world's largest independent pharmaceutical company specializing in dermatology, announced that a recent study shows MimyX Cream extends the remission period of atopic dermatitis (AD) by 48 percent when used in conjunction with an emollient compared to emollient alone.

6 Mar 2006

New test from Biomarker Technologies assists in early detection for Breast Cancer

Phoenix-based Biomarker Technologies announced the launch of a clinical study for its revolutionary blood test that detects breast cancer. Previous clinical studies have shown the test to significantly exceed the accuracy of mammograms.

6 Mar 2006

Study shows Differin Gel works well in combination with systemic or other topical agents

Findings from the M.O.R.E. (Measuring Outcomes in A Real World Experience) Trial presented at the 64th annual meeting of the American Academy of Dermatology (AAD) show that Differin Gel 0.1% is a topical retinoid preparation that, when combined with other acne products, dramatically improves the efficacy of an acne regimen.

6 Mar 2006

Schering-Plough provides update on phase II study of Vicriviroc

Schering-Plough Corporation has provided an update on vicriviroc, its investigational CCR5 receptor antagonist, currently being evaluated by the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) in an ongoing Phase II clinical study of 118 U.S. treatment-experienced HIV patients.

6 Mar 2006

Orthopaedic medical device technologies that offer greater clinical benefits expected to succeed

Current users of medical device technologies for orthopaedic applications seek systems that offer maximum comfort while requiring minimum physical supervision. This is driving the market to continuously evolve technologies that use radically different approaches or make significant improvements to existing products.

6 Mar 2006